-
"Development Status of National Intellectual Property Agency Industry (2022)" shows that China's intellectual property agency industry keeps healthy development
2025-05-07According to statistical data analysis, the characteristics of Chinas intellectual property agency industry are as follows:In 2022, 645 new patent agencies were established nationwide, and 5 foreign patent agencies were approved to establish resident representative offices. As of the end of 2022, th -
Chinese enterprises account for half of 5G standard essential patents with Huawei ranking first, and Xiaomi entering the top 10 for the first time
2025-05-07Recently, CAICT (China Academy of Information and Communications Technology) released the "Research Report on Global 5G Standard-Essential Patents and Standard Proposals (2023)". This year, a total of 5 Chinese brands are included in the top 10 list, one more than that of last year, now making up ha -
MGI’s patent litigation "against the giant" makes a breakthrough
2025-05-07In February this year, MGIs newly released DNBSEQ-T20×2 ultra-high-throughput sequencer won the champion for global sequencing throughput. In March, MGI won again in the patent dispute over the global gene sequencing giant Illumina. It is reported that on March 30, 2023, the Appeal Committee of the -
Beijing’s amount of invention patents per 10,000 people ranks first in China
2025-05-07The number of patent authorizations in Beijing in 2022 exceeds 200,000, the number of invention patents per 10,000 people ranks first over the country, the number of industrial intellectual property operation centers ranks first in China, and the comprehensive strength of intellectual property conti -
Junshi Biosciences launches a "patent challenge" against Novartis: generic drugs and original pharmaceutical companies engage in a fiercer competition
2025-05-07In recent years, disputes over innovative drug patents have continuedly happened. Recently, CNIPA issued an oral examination announcement stating that the patent of Alnylam Pharmaceuticals, Inc. with the application number "2013800639305" and the invention name "PCSK9 iRNA composition and its method